Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ph Gabriel Steg

Showing results (11-20 of 229) with videos related to

Pageof 23
Sort By:
Circulation|April 20, 2018
Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITADeepak L Bhatt, Bernard J Gersh, Ph Gabriel Steg, et al.
Cardiovascular Therapeutics|September 3, 2011
Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian CohortZanfina Ademi, Danny Liew, Bruce Hollingsworth, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 26, 2010
Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registryZanfina Ademi, Danny Liew, Bruce Hollingsworth, et al.
Cardiovascular Research|January 22, 2024
Do patients benefit from omega-3 fatty acids?Samuel C R Sherratt, R Preston Mason, Peter Libby, et al.
International Journal of Cardiology|June 13, 2017
Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysisAnubodh Varshney, Ph Gabriel Steg, Yedid Elbez, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|July 8, 2010
Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in EuropeJonathan Morrell, Uwe Zeymer, Iris Baumgartner, et al.
American Heart Journal|June 23, 2009
Renal function, atherothrombosis extent, and outcomes in high-risk patientsRaphaelle L Dumaine, Gilles Montalescot, Ph Gabriel Steg, et al.
JACC. Cardiovascular Interventions|March 25, 2017
Long-Term Outcomes of Stenting the Proximal Left Anterior Descending Artery in the PROTECT TrialAriel Roguin, Edoardo Camenzind, Arthur Kerner, et al.
Journal of Clinical Lipidology|June 30, 2022
Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-ITPrakriti Gaba, Deepak L Bhatt, R Preston Mason, et al.
Cardiovascular Therapeutics|April 16, 2013
The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registryZanfina Ademi, Molla M Huq, Danny Liew, et al.
Pageof 23

Showing results (11-20 of 229) with videos related to

Sort By:
Pageof 23
Circulation|April 20, 2018
Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITADeepak L Bhatt, Bernard J Gersh, Ph Gabriel Steg, et al.
Cardiovascular Therapeutics|September 3, 2011
Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian CohortZanfina Ademi, Danny Liew, Bruce Hollingsworth, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 26, 2010
Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registryZanfina Ademi, Danny Liew, Bruce Hollingsworth, et al.
Cardiovascular Research|January 22, 2024
Do patients benefit from omega-3 fatty acids?Samuel C R Sherratt, R Preston Mason, Peter Libby, et al.
International Journal of Cardiology|June 13, 2017
Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysisAnubodh Varshney, Ph Gabriel Steg, Yedid Elbez, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|July 8, 2010
Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in EuropeJonathan Morrell, Uwe Zeymer, Iris Baumgartner, et al.
American Heart Journal|June 23, 2009
Renal function, atherothrombosis extent, and outcomes in high-risk patientsRaphaelle L Dumaine, Gilles Montalescot, Ph Gabriel Steg, et al.
JACC. Cardiovascular Interventions|March 25, 2017
Long-Term Outcomes of Stenting the Proximal Left Anterior Descending Artery in the PROTECT TrialAriel Roguin, Edoardo Camenzind, Arthur Kerner, et al.
Journal of Clinical Lipidology|June 30, 2022
Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-ITPrakriti Gaba, Deepak L Bhatt, R Preston Mason, et al.
Cardiovascular Therapeutics|April 16, 2013
The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registryZanfina Ademi, Molla M Huq, Danny Liew, et al.
Pageof 23